Stevanato Group S.p.A. (STVN) Reports Q4 EPS of EUR0.13
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Stevanato Group Reports Record 2021 Revenue of €843.9 million
March 8, 2022 6:30 AM EST- Establishes Full Year 2022 Guidance -
PIOMBINO DESE, Italy--(BUSINESS WIRE)-- Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the fourth quarter 2021.
Fourth Quarter and Full Year Highlights (compared to the same period last year)
Fourth quarter revenue increased 12.5% to 232.6 million, diluted EPS were 0.17 and adjusted diluted EPS were 0.13. Adjusted EBITDA margin was 25.3%, Full year revenue grew 27.5% to 843.9 million, diluted EPS were... More